Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs....
Summary YBL-001은 암세포에 발현된 DLK1에 특이적으로 결합하여 세포내로 유입 가능한 항체에 세포 사멸기능을 갖는 약물(drug)을 접합하여 만든 항체-약물 접합체 (antibody-drug conjugates, ADC)인 DLK1-ADC이며, 간암, 대장암, 유방암, 소세포성 폐암, 섬세포성 췌장암 등 에서 과발현이 되어 있고, 암줄기 세포의 바이오 마커로서 암의 재발과 전이에 관련한다고 보고되어 있습니다. DLK1-ADC는 DLK1 발현 암세포에 특이적으로 결합하 ...
Antibody-oligonucleotide conjugates or AOCs belong to a class of chimeric molecules combining in their structure two important families of biomolecules: monoclonal antibodies and oligonucleotides. Combination of exceptional targeting capabilities of monoclonal antibodies with numerous func...
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic agents, potentially reducing the severity of side effects by preferentially tar...
Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full potential of this...
Show full caption View Large Image Download Hi-res image Download (PPT) Figure 2Rationale for antibody–drug conjugate (ADC)-based combination therapies. Show full caption View Large Image...
Molecular Probes Antibody Conjugate Purification kits efficiently purify antibody conjugates from unconjugated dye or biotin. This particular kit is optimized for the purification of 2050 g of anti...
: Structural Design, AOCs: Antibodies, linkers, oligonucleotides (siRNA, ASO, Aptamer, etc.) ; : OAR of AOC & DAR of ADC Analysis, AOCs: OAR (Oligonucleotide-to-Antibody Ratio) is a parameter used to describe the ratio of oligonucleotides to antibodies. The testing of OAR focuses on the analysis of oligonucleotide modifications. ; : Application, AOCs: Therapeutics, imaging, detection
Antibody drug conjugates (ADCs) have emerged as a promising class of targeted cancer therapies in recent years. ADCs, composed of monoclonal antibodies linked to a cytotoxic drug, are designed to s...
Despite a prevailing dogma wherein antibody drug conjugates (ADCs) increase the maximum tolerated dose of potent cytotoxin payloads while lowering the minimum effective dose, mounting clinical evid...